Related Experiment Videos
New anticancer agents in clinical development
J Eckardt1, G Eckhardt, M Villalona-Calero
1Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, USA.
Abstract:
A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; the paclitaxel analog docetaxel; gemcitabine, an antimetabolite structurally related to cytarabine; and fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors. Another exciting approach to cancer treatment is the use of agents that induce a less malignant state by altering cellular phenotype. Such agents include angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.
Insights
New cancer treatments are being developed, including novel antineoplastic compounds and agents that alter the cancer cell phenotype. These innovative therapies target key cellular processes for improved patient outcomes.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Advances in understanding cancer cell biology and biochemistry have spurred the development of novel antineoplastic compounds.
- Current research focuses on drugs targeting critical cellular pathways and agents that modify the cancer cell phenotype.
Purpose of the Study:
- To review promising new antineoplastic compounds and phenotypic-altering agents in clinical development.
- To highlight the diverse strategies being explored for more effective cancer treatment.
Main Methods:
- Review of ongoing phase I, II, and III clinical trials for new cancer therapeutics.
- Categorization of novel agents based on their mechanism of action, including topoisomerase I inhibitors, antimetabolites, and phenotypic modulators.
Main Results:
- Several classes of antineoplastic compounds are in advanced clinical testing, including camptothecin analogs (9-aminocamptothecin, irinotecan, topotecan), docetaxel, gemcitabine, and thymidylate synthase (TS) inhibitors.
- Emerging therapeutic strategies involve agents that induce a less malignant state, such as angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.
Conclusions:
- A deeper understanding of cancer biology is driving the development of targeted therapies.
- Multiple promising avenues, from direct cytotoxic agents to phenotype-modifying strategies, are advancing cancer treatment research.